Cell-derived nanoparticles, so called Extracellular Vesicles (EVs), can reflect the physiological or pathological conditions of donor cells and can provide promising biomarkers for the non-invasive diagnosis of cancers. Size-based purification method is one of the common strategies for rapid extracting EVs from biosamples, but the downstream clinical studies still remain challenges in EV enrichment with high purity and high yield. Here, such challenges could be fulfilled through the development of an arrayed Exosome Purification and Operation System (Exo-POS) for efficiently isolating EVs from complex biofluids. Human urinary EVs with mean size of approximately 170 nm were isolated successfully from donors within 30 min, and the purification of individual samples were performable in parallel. Samples purified by Exo-POS showed detectable EV-specific biomarkers and less protein impurities than that by ultrafiltration method. The results also demonstrate the great purification ability of Exo-POS to discriminate between the EV-derived proteomic and genomic expressions of cancer patients and healthy controls. The developed platform can easily be adapted to retrieve EVs from biological samples for the downstream analysis, demonstrating its potential for both rapid clinical diagnosis and biomarker discovery.

中文翻译：

---

一种用于癌症检测的简便、快速、高通量的细胞外囊泡分析平台

细胞衍生的纳米颗粒，即所谓的细胞外囊泡 (EVs)，可以反映供体细胞的生理或病理状况，并可以为癌症的非侵入性诊断提供有希望的生物标志物。基于尺寸的纯化方法是从生物样品中快速提取 EV 的常用策略之一，但下游临床研究在高纯度和高产量的 EV 富集方面仍然存在挑战。在这里，可以通过开发阵列外泌体纯化和操作系统 (Exo-POS) 来解决这些挑战，以有效地将 EV 与复杂的生物流体分离。在 30 分钟内从供体中成功分离出平均大小约为 170 nm 的人类尿液 EV，并且可以并行执行单个样品的纯化。与超滤方法相比，Exo-POS 纯化的样品显示出可检测的 EV 特异性生物标志物和更少的蛋白质杂质。结果还证明了 Exo-POS 在区分癌症患者和健康对照的 EV 衍生的蛋白质组和基因组表达方面的强大纯化能力。开发的平台可以很容易地适应从生物样本中检索 EV 以进行下游分析，证明其在快速临床诊断和生物标志物发现方面的潜力。